174 related articles for article (PubMed ID: 23326330)
21. Knockdown of MDR1 increases the sensitivity to adriamycin in drug resistant gastric cancer cells.
Zhu CY; Lv YP; Yan DF; Gao FL
Asian Pac J Cancer Prev; 2013; 14(11):6757-60. PubMed ID: 24377601
[TBL] [Abstract][Full Text] [Related]
22. Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.
Mirandola L; Chiriva-Internati M; Montagna D; Locatelli F; Zecca M; Ranzani M; Basile A; Locati M; Cobos E; Kast WM; Asselta R; Paraboschi EM; Comi P; Chiaramonte R
J Pathol; 2012 Apr; 226(5):713-22. PubMed ID: 21984373
[TBL] [Abstract][Full Text] [Related]
23. CCR9 and CCL25: A review of their roles in tumor promotion.
Xu B; Deng C; Wu X; Ji T; Zhao L; Han Y; Yang W; Qi Y; Wang Z; Yang Z; Yang Y
J Cell Physiol; 2020 Dec; 235(12):9121-9132. PubMed ID: 32401349
[TBL] [Abstract][Full Text] [Related]
24. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells.
Kamioka H; Edaki K; Kasahara H; Tomono T; Yano K; Ogihara T
J Pharm Pharmacol; 2021 Dec; 73(12):1609-1616. PubMed ID: 34313784
[TBL] [Abstract][Full Text] [Related]
26. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.
Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M
Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
28. Differential involvement of ezrin/radixin/moesin proteins in sphingosine 1-phosphate-induced human pulmonary endothelial cell barrier enhancement.
Adyshev DM; Moldobaeva NK; Elangovan VR; Garcia JG; Dudek SM
Cell Signal; 2011 Dec; 23(12):2086-96. PubMed ID: 21864676
[TBL] [Abstract][Full Text] [Related]
29. Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Lucia MB; Anu R; Handley M; Gillet JP; Wu CP; De Donatis GM; Cauda R; Gottesman MM
Br J Cancer; 2011 Aug; 105(4):513-22. PubMed ID: 21829205
[TBL] [Abstract][Full Text] [Related]
30. CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis.
Wurbel MA; Le Bras S; Ibourk M; Pardo M; McIntire MG; Coco D; Geha RS; Fiebiger E; Snapper SB
Inflamm Bowel Dis; 2014 Jul; 20(7):1165-76. PubMed ID: 24874458
[TBL] [Abstract][Full Text] [Related]
31. CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.
Li B; Wang Z; Zhong Y; Lan J; Li X; Lin H
Med Oncol; 2015 Mar; 32(3):66. PubMed ID: 25691296
[TBL] [Abstract][Full Text] [Related]
32. CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.
Sharma PK; Singh R; Novakovic KR; Eaton JW; Grizzle WE; Singh S
Int J Cancer; 2010 Nov; 127(9):2020-30. PubMed ID: 20127861
[TBL] [Abstract][Full Text] [Related]
33. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study.
Ivy SP; Olshefski RS; Taylor BJ; Patel KM; Reaman GH
Blood; 1996 Jul; 88(1):309-18. PubMed ID: 8704189
[TBL] [Abstract][Full Text] [Related]
34. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.
Amersi FF; Terando AM; Goto Y; Scolyer RA; Thompson JF; Tran AN; Faries MB; Morton DL; Hoon DS
Clin Cancer Res; 2008 Feb; 14(3):638-45. PubMed ID: 18245522
[TBL] [Abstract][Full Text] [Related]
35. Increased CCL25 and T Helper Cells Expressing CCR9 in the Salivary Glands of Patients With Primary Sjögren's Syndrome: Potential New Axis in Lymphoid Neogenesis.
Blokland SLM; Hillen MR; Kruize AA; Meller S; Homey B; Smithson GM; Radstake TRDJ; van Roon JAG
Arthritis Rheumatol; 2017 Oct; 69(10):2038-2051. PubMed ID: 28622456
[TBL] [Abstract][Full Text] [Related]
36. Intracellular expression profile and clinical significance of the CCR9-CCL25 chemokine receptor complex in nasopharyngeal carcinoma.
Ye LF; Huang J; Zhang LP; Chen Z
J Laryngol Otol; 2015 Oct; 129(10):1013-9. PubMed ID: 26279399
[TBL] [Abstract][Full Text] [Related]
37. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease.
Apostolaki M; Manoloukos M; Roulis M; Wurbel MA; Müller W; Papadakis KA; Kontoyiannis DL; Malissen B; Kollias G
Gastroenterology; 2008 Jun; 134(7):2025-35. PubMed ID: 18439426
[TBL] [Abstract][Full Text] [Related]
38. Activation of ezrin/radixin/moesin mediates attractive growth cone guidance through regulation of growth cone actin and adhesion receptors.
Marsick BM; San Miguel-Ruiz JE; Letourneau PC
J Neurosci; 2012 Jan; 32(1):282-96. PubMed ID: 22219290
[TBL] [Abstract][Full Text] [Related]
39. Actin microdomains on endothelial cells: association with CD44, ERM proteins, and signaling molecules during quiescence and wound healing.
Jensen PV; Larsson LI
Histochem Cell Biol; 2004 May; 121(5):361-9. PubMed ID: 15103468
[TBL] [Abstract][Full Text] [Related]
40. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.
Singh R; Stockard CR; Grizzle WE; Lillard JW; Singh S
Int J Oncol; 2011 Aug; 39(2):373-81. PubMed ID: 21637913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
